Tenax Therapeutics (TENX) EBITDA (2010 - 2026)

Tenax Therapeutics (TENX) has 16 years of EBITDA data on file, last reported at -$16.6 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 46.17% year-over-year to -$16.6 million; the trailing twelve-month figure through Mar 2026 stood at -$61.6 million (down 128.87% YoY), and the FY2025 full-year result was -$56.4 million, down 189.24% from the prior year.
• EBITDA declined to -$16.6 million in Q1 2026, from -$16.4 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $2.9 million in Q3 2022 to a low of -$16.8 million in Q3 2025.
• A 5-year average of -$5.5 million and a median of -$3.9 million in 2024 frame the typical range for EBITDA.
• Across the five-year window, EBITDA jumped 104.1% in 2022 and tumbled 613.85% in 2023, its largest moves.
• Tracing TENX's EBITDA over 5 years: stood at $2.6 million in 2022, then plunged by 613.85% to -$13.1 million in 2023, then jumped by 44.43% to -$7.3 million in 2024, then slumped by 125.48% to -$16.4 million in 2025, then fell by 0.75% to -$16.6 million in 2026.
• Business Quant data shows TENX's EBITDA at -$16.6 million in Q1 2026, -$16.4 million in Q4 2025, and -$16.8 million in Q3 2025.